Cyclosporiasis CDC Summary

Cyclosporiasis is a gastrointestinal infection caused by Cyclospora cayetanensis (italics), typically acquired from contaminated fresh produce or water. In 2026, the CDC reported a major surge in domestically acquired cases, with 1,645 lab-confirmed U.S. cases since May 1 and awareness of 5,100+ additional reports pending confirmation. Cases were reported across 34 states, with 141 hospitalizations and no deaths. Symptoms include prolonged watery diarrhea, loss of appetite, weight loss, bloating, nausea, and fatigue. Routine ova & parasite (O&P) exams often miss Cyclospora, so clinicians must specifically request Cyclospora testing, ideally PCR-based, which improves detection.

CDC, FDA, and state health departments are investigating multiple outbreaks, including a large multistate cluster likely linked to a common food source. Outbreak investigations are challenging due to delayed symptom onset and limited genotyping tools. 🧪 IVD Companies with Cyclospora / Cyclosporiasis Testing Below is a structured, diagnostics-focused breakdown of who offers testing and which methodologies are available, based strictly on sourced information.

1. ARUP Laboratories (U.S.) Test Type: Stool O&P exam with AI-enhanced microscopy. Methodology: • Modified acid-fast stain for Cyclospora oocysts (the preferred stain because trichrome does not penetrate the oocyst wall). • AI assisted screening of trichrome, wet mounts, and modified acid fast slides to improve sensitivity. • Not a molecular assay; this is microscopy-based detection enhanced by AI algorithms. Notes: ARUP is currently the only reference lab using AI-enhanced parasite screening across the entire O&P workflow.

2. Rheonix Inc. (U.S.) Test Type: Fully automated molecular assay for Cyclospora cayetanensis. Methodology: • PCR based genetic detection using FDA published genetic targets. • Runs on the Rheonix Encompass Optimum™ microfluidic workstation. • Designed for food and environmental samples, not clinical stool testing. Notes: Although not an IVD for human diagnostics, Rheonix’s assay is important for outbreak traceback and agricultural surveillance.

3. Other Clinical IVD Manufacturers - Based on CDC guidance and available sources, no major commercial clinical IVD manufacturers (e.g., BioFire, Luminex, Seegene, Cepheid, Abbott, Roche) are documented as offering a Cyclospora-specific FDA-cleared clinical assay.

CDC notes that molecular PCR testing improves detection but does not list any specific FDA-cleared commercial panels, including those for Cyclospora. Many GI multiplex panels cover Cryptosporidium, Giardia, and other pathogens, but Cyclospora is typically not included. This aligns with the CDC’s statement that clinicians must specifically request Cyclospora testing, implying limited availability in standard multiplex panels.

🧬 Summary of Testing Methodologies 1. Modified Acid-Fast Stain Microscopy - Highlights Cyclospora oocysts; standard for detection; requires trained microscopists. 2. AI-Enhanced Microscopy - Automated image analysis to improve sensitivity in O&P exams.
3. PCR / Molecular Detection Detects Cyclospora DNA; higher sensitivity; recommended by CDC when available. 4. Wet Mount / Trichrome Stains - Traditional O&P methods; low sensitivity for Cyclospora.

🔍 Executive Takeaway for Diagnostics Strategy • Clinical detection remains largely microscopy-based, with ARUP providing the most advanced implementation through AI-enhanced O&P workflows. • Molecular detection exists but is not widely commercialized for clinical IVD use; instead, it is used in public health and food safety surveillance (e.g., Rheonix + FDA). • CDC explicitly recommends PCR when available, signaling a future need/opportunity for IVD manufacturers to add Cyclospora to GI multiplex panels.